ESTRO 2020 Abstract book

S34 ESTRO 2020

review was prompted to assess carefully selected elderly patient’s tolerance to radical RT to the H&N. Material and Methods Patient information was gained from the department’s RT database and the trusts clinical record system. Descriptive statistics were generated using 148 patients were retrospectively reviewed, aged 70 or above. Patients had received radical radiotherapy to the H&N – either as primary or adjuvant treatment between January 2012 and August 2015. Patient characteristics, treatment details and compliance are displayed in table 1. 140 (95%) patients completed their RT course, although 72 (49%) patients were admitted to hospital within 6 months of completing RT. The mean number of days spent in hospital was 12 (SD 24). 108 (73%) patients were able to continue living in their own home at 12 months post RT. 60 (41%) patients experienced a relapse of their H&N disease. The mean number of days to relapse was 373 (SD 369). 29 relapses were loco-regional and 31 were distal. Of the patients with loco-regional relapse 3 underwent salvage surgery. 59 (40%) patients died within 2 years of completing RT. 45 (76%) died as a result of their cancer diagnosis while the remaining 14 (23%) died due to other causes. Median patient survival for all patients was 38 months (95% CI 27.2-45.5 months). Patient survival was stratified by age; median survival of 28.9 months (95%CI 18.8 to 39.3) for the 70 to 75 years group and 45.1 months (95%CI 32.7 to 53.2) for those greater than 75 years. Table 2 displays patient’s median survival by treated sub- site. Patients with hypopharyngeal SCC had a short median survival, in keeping with the recognised poor prognosis in this sub-site. A careful assessment must be made in these patients in particular, balancing the toxicity and general impact of treatment with the small likelihood of long term disease control despite a radical approach. STATA. Results

Conclusion This data provides reassurance that radical RT is a feasible option in appropriately selected older patients with H&N cancers. The majority of patients completed their radical RT course with no unscheduled gap in treatment, suggesting our current subjective approach to assessing fitness for treatment is accurate. This study does not evaluate patients deemed unfit for radical RT. Therefore our current selection process may be too stringent and more patients could potentially tolerate radical RT. The effects of RT on these patients should not be underestimated and an additional tool such as a formal geriatric or frailty assessment could further improve our patient selection. OC-0074 Impact of early diagnosis and improved access to treatment on lung cancer survival T. Mee 1,2 , S. Brown 3 , N.F. Kirkby 1,2 , N.G. Burnet 1,2 , C. Faivre-Finn 1,2 , K.J. Kirkby 1,2 1 University Of Manchester, Division of Cancer Sciences, Manchester, United Kingdom ; 2 The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom ; 3 The Clatterbridge Cancer Centre, Radiation Oncology, Wirral, United Kingdom Purpose or Objective Lung cancer(LC) screening aims to improve early diagnosis in patients at high risk. Trials have shown low-dose CT screening can improve LC mortality by 20% 1 . If a successful national screening program(NSP) is implemented, there could be a large impact upon health services. SABR for early stage LC is the standard of care for patients unsuitable for surgery. However, SABR is not commissioned in 30% of English radiotherapy(RT) centres 2 . Numbers of patients who receive suboptimal conventional RT or no treatment are unacceptably high compared to The Netherlands(26% vs 9%) 3 . The aim of this study is to estimate the increase of stage1 LC patients with a NSP and to estimate demand for SABR, RT, surgery and no treatment in that population, using current English rates and aspirational Dutch rates. Material and Methods Results from the Manchester Lung Health Check(MLHC) pilot 1 were applied to England, at a clinical commissioning group(CCG) level, by using propensity score matching. Stage data, age-banded incidence data, population data Proffered Papers: Proffered papers 1: HSR HERO